165 results on '"Eriksen, Erik Fink"'
Search Results
2. Intermittent dosing of zoledronic acid based on bone turnover marker assessment reduces vertebral and non-vertebral fractures.
3. Bisphosphonates as a treatment modality in osteoarthritis
4. Relationships Between Vitamin D Status and PTH over 5 Years After Roux-en-Y Gastric Bypass: a Longitudinal Cohort Study
5. Bone metabolism, bone mineral density and low-energy fractures 10 years after Roux-en-Y gastric bypass
6. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS
7. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
8. High-sensitivity C-reactive protein is an independent risk factor for non-vertebral fractures in women and men: The Tromsø Study
9. Reduced Bone Material Strength is Associated with Increased Risk and Severity of Osteoporotic Fractures. An Impact Microindentation Study
10. Relationships of serum 25‐hydroxyvitamin D, ionized calcium and parathyroid hormone after obesity surgery
11. Disease-Modifying Adjunctive Therapy of Osteopenia and Osteoporosis with a Multimineral Marine Extract, LithoLexal ® Bone.
12. Use of Bone Turnover Markers in Monitoring Osteoporosis Treatment in Patients with Fragility Fractures: Target Values and Daytime Variation
13. Bone Turnover in Relation to Thyroid-Stimulating Hormone in Hypothyroid Patients on Thyroid Hormone Substitution Therapy.
14. Excessive Decrease in Serum Magnesium After Total Thyroidectomy for Graves’ Disease Is Related to Development of Permanent Hypocalcemia
15. Treatment of osteopenia
16. Bone marrow lesions: a universal bone response to injury?
17. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis
18. Cellular mechanisms of bone remodeling
19. Thyroid Signaling Biomarkers in Female Symptomatic Hypothyroid Patients on Liothyronine versus Levothyroxine Monotherapy: A Randomized Crossover Trial.
20. Effects of anticatabolic and anabolic therapies at the tissue level
21. Zoledronic acid and clinical fractures and mortality after hip fracture
22. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
23. New developments in the treatment of osteoporosis
24. Vitamin D deficiency and aging: implications for general health and osteoporosis
25. Effect of Liothyronine Treatment on Quality of Life in Female Hypothyroid Patients With Residual Symptoms on Levothyroxine Therapy: A Randomized Crossover Study.
26. Disease-Modifying Adjunctive Therapy (DMAT) in Osteoarthritis--The Biological Effects of a Multi-Mineral Complex, LithoLexal® Joint--A Review.
27. Efficacy and Safety of a Once-Yearly Intravenous Zoledronic Acid 5 mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older
28. Effect of Liothyronine Treatment on Dermal Temperature and Activation of Brown Adipose Tissue in Female Hypothyroid Patients: A Randomized Crossover Study.
29. Impact of osteonecrosis of the jaw on osteoporosis management: executive summary of an ESCEO and Foundation for Research on Osteoporosis and other Bone Diseases Working Group Meeting
30. In memoriam:Leif Mosekilde
31. Leif Mosekilde IN MEMORIAM
32. The von Kossa reaction for calcium deposits: silver lactate staining increases sensitivity and reduces background
33. Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis
34. The Norwegian Capture the Fracture Initiative a stepped wedge cluster randomized 1 controlled trial of a Fracture Liaison Service model of care: The NoFRACT Trial Protocol
35. Consensus development statement on osteoporosis
36. B Vitamins and Hip Fracture: Secondary Analyses and Extended Follow-Up of Two Large Randomized Controlled Trials
37. Novel findings in gene expression detected in human osteosarcoma by cDNA microarray
38. Changes in Bone Marrow Adipose Tissue One Year After Roux‐en‐Y Gastric Bypass: A Prospective Cohort Study.
39. Osteonecrosis after intranasal injection with bevacizumab in treating hereditary hemorrhagic telangiectasia: A case report.
40. Anabolics.
41. Establishment of a tear protein biomarker panel differentiating between Graves’ disease with or without orbitopathy.
42. High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial.
43. Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study.
44. Vitamin D deficiency and aging:implications for general health and osteoporosis
45. Response to letter to the editor by Leder et al. regarding commentary “Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics”
46. Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics
47. Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice.
48. Chapter 35 - Validation of Biochemical Markers of Bone Turnover
49. Characteristics of Glucose Metabolism in Nordic and South Asian Subjects with Type 2 Diabetes.
50. Bone Turnover and Metabolism in Patients with Early Multiple Sclerosis and Prevalent Bone Mass Deficit: A Population-Based Case-Control Study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.